National Comprehensive Cancer Network


Video Modules

FDA Watch

Taped March 9, 2011 in Hollywood, Florida

This module addresses FDA considerations such as:
  • FDA/CMS Parallel Review: Will it happen, How often and Implications for the Introduction of drugs and biologics
  • Accelerated Approval and Phase IV Study requirements: Will the FDA continue to ratchet down on this “Requirement”
  • Supplemental Indications: Can outside expertise (e.g., NCCN) supplement ODAC and FDA; Would FDA be open to this as a collaboration
  • Safety and Effectiveness: Will comparative effectiveness and cost considerations be added as data requirements
  • REMS: FDA’s view after initial introductions of REMS programs and feedback
  • Clinical Outcomes as Regulatory End Points in Cancer Care; Is progression free survival enough, e.g., with a driver gene is substantial response rate sufficient


Panelists:

  • Scott  Gottlieb, MD, American Enterprise Institute (Moderator)
  • William  T.  McGivney, PhD, National Comprehensive Cancer Network (NCCN) (Moderator)
  • Al  B.  Benson III, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Randy  Burkholder, Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Kathleen  M.  Sanzo, Morgan, Lewis & Bockius FDA and Healthcare Practice
  • Elizabeth  Thompson, Susan G. Komen for the Cure

+ View Faculty Information

To learn more about NCCN Academy Video Modules or to take advantage of discounted Corporate Council rates for licensing of the NCCN Academy Video Modules, please contact Jennifer Tredwell


File Size: 123 MB       Length: 73 minutes       Last Updated: 07/20/2011

1-year subscription $5,000.00